stockrow
Friday 6 November 2026
Export RDHL’s income statement to Excel — free account
Redhill Biopharma Ltd.
RDHL Healthcare Drug Manufacturers Specialty & Generic
Redhill Biopharma Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $286,000.00, down 96.4% from fiscal 2024.
0.43
0.00
0.00%
Follow RDHL
Alert me
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 |
+8 more TTM periods Free account |
| 0.00% | 0.00% | 0.00% | (181.89%) | ||
| 0.00% | 0.00% | 0.00% | 7.59% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | (858.65%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 34.67 | |
Free Cash Flow per Share |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (19.66) | (31.24) | (33.53) | |
Capital Expenditures |
— | (0.01) | (0.03) | (0.19) | |
| Other line items | |||||
Cash ROIC |
0.00% | 1,418.54% | (386.84%) | (170.88%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 1.67 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 5.29 | |
Inventory Turnover |
— | 0.00 | 0.00 | 2.38 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 57.33 | |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 90.98 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 16.53% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 144.88% | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 12.25% | |
Interest Coverage |
— | — | — | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | (4.33) | |
Depreciation/Fixed assets |
0.00 | 37.19 | 54.66 | 268.87 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
— | — | — | 0.00 | |
Operating CF per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.01 |
Columns are period end dates · fundamentals updated 26 Oct 2026